GROUNDBREAKING STUDY LAUNCHES

"Intermountain launches groundbreaking study using the PreTRM test to prevent preterm birth." Read more here

DOCTORS SPEAK OUT

"Women want good information. If a test predicts that they might have a preterm birth, they want to know."

PROTEOMIC INNOVATION

PreTRM Test Featured in Top-Tiered Scientific Journal as Example of Proteomic Test That Advances Patient Care. Read More

DOCTORS SPEAK OUT

"The value of the PreTRM test cannot be overestimated. We continue to deal with the vast majority of women who eventually go into preterm labor and deliver early with having absolutely no identifiable risk factors." Watch Dr. Shulman's video here

PROTEOMIC INNOVATION

“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO

DOCTORS SPEAK OUT

"With 1 in 10 women in the United States delivering prematurely, I believe every woman is an excellent candidate for the PreTRM test." Watch Dr. Mandel's video here

News

SERA PROGNOSTICS TO PRESENT AT THE BTIG VIRTUAL MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTIC TOOLS CONFERENCE

Sera Prognostics, Inc., a leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Read More >

AMERICAN MEDICAL ASSOCIATION (AMA) GRANTS SERA PROGNOSTICS A CPT® PLA CODE FOR PreTRM®, THE ONLY BROADLY VALIDATED BLOOD TEST TO ASSESS RISK OF PRETERM BIRTH

February 3, 2021- Receipt of dedicated CPT® code marks important commercialization milestone to pursue reimbursement for the PreTRM® Test. Read More >

Sera Prognostics Partners With Anthem and HealthCore to Improve Outcomes for Preterm Babies

January 05, 2021- Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care. Read More >

WHO WE ARE

PROVIDING INDIVIDUALIZED RISK ASSESSMENT TO PREDICT AND MANAGE PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS

Sera Prognostics is dedicated to improve the lives of women and babies through individualized prenatal care.  Sera’s strategy is to deliver pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women.  Our first test, the PreTRM® Test, focuses on the early prediction of preterm birth risk, one of the most serious pregnancy complications which affects almost one in ten pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better understand risks and proactively address risks of adverse pregnancy outcomes.  Learn about the PreTRM® Test for Risk Management.